Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03460483 · ClinicalTrials.gov registry record · NA
Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 1,001
- Enrollment target
NCT03460483: Completed NA study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT03460483 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 1,001 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03460483, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,001 participants
- Enrollment target
Study Summary
This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.
Primary Outcome
Measured by molecular profiling of tumor deoxyribonucleic acid (DNA) via next-generation sequencing.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Genetic Testing
- OTHER Genetic Counseling
- PROCEDURE Mutation Carrier Screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,001 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2025-06-15 |
| Phase | NA |
What the finished NCT03460483 record still lists
NCT03460483 is an interventional study that assigns participants to a tested intervention. Its 1,001 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03460483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03460483 about?
NCT03460483 is a clinical study titled "Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care". This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strateg...
What is the current status of trial NCT03460483?
This trial is currently completed. It is a NA study. The enrollment target is 1,001 participants. The study started on 2018-03-30. Estimated completion is 2025-06-15.
What interventions are being tested in trial NCT03460483?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Genetic Testing (OTHER), Genetic Counseling (OTHER), Mutation Carrier Screening (PROCEDURE).
Who is sponsoring clinical trial NCT03460483?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03460483's enrollment target sits among peer trials
1,001 106th of 2000 higher than 1,894 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI